Continuing Medical Education Posttest
The following Topics in Antiviral Medicine™ issue offers continuing medical education (CME) credit:
December 2016/January 2017, Volume 24, Issue 4
- CME Credit Available: 3.25 AMA PRA Category 1 Credits™
- Release Date: January 31, 2017
- Expiration Date: January 31, 2018
To complete the activity, read each article and successfully complete the posttest and evaluation form, which will help us evaluate this activity and plan future activities. Your responses will not affect your CME credit.
On completion of this activity, participants will be able to:
- Describe the efficacy and safety of preexposure prophylaxis (PrEP) for HIV prevention and emerging PrEP modalities
- List methods for predicting cardiovascular disease (CVD) risk as well as complications of CVD in the context HIV infection
- Describe hot topics and emerging data in HIV research, prevention, and care
Assessment of Needs
The IAS–USA offers this state-of-the-art activity as part of a nationwide CME effort for physicians on the evolving challenges of managing HIV disease.
This enduring material is designed for physicians and other health care practitioners who are actively involved in the medical care of people with HIV infection.
This activity is also relevant for other practitioners, including nurse practitioners, nurses, physician assistants, pharmacists, and others.
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The IAS–USA designates this enduring material for a maximum of 3.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This CME activity is offered from January 31, 2017, to January 31, 2018. Participants who successfully complete the activity posttest and submit the evaluation and registration forms are eligible to receive CME credit. Physicians (MDs, DOs, and international equivalents) may receive CME credit for completing this activity. Other health care practitioners will receive a certificate of participation.
Disclosure of Financial Interests
In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (ie, authors, IAS–USA Board members, and program staff) to disclose any financial relationships that they (or their spouses or partners) have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the continuing medical education activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.
Dr Benson serves on a data and safety monitoring board for GlaxoSmithKline/ViiV Healthcare. She has received research grants awarded to her institution from AbbVie, Gilead Sciences, Inc, and ViiV Healthcare. Information for her spouse, Dr Robert T. Schooley, is included below. (Updated 01/20/17)
Dr Currier has no relevant financial affiliations to disclose. (Updated 01/19/17)
Dr del Rio has served as a consultant for InnaVir-Vax. (Updated 01/17/17)
Dr Gallant has served as a consultant or advisor to Bristol-Myers Squibb, Gilead Sciences, Inc, Janssen Therapeutics, Merck & Co, Inc, and ViiV Healthcare/GlaxoSmithKline. He has received research grants or contracts awarded to his institution from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Inc, Janssen Therapeutics, Inc, Merck & Co, Inc, Sangamo BioSciences, and ViiV Healthcare/GlaxoSmithKline. (Updated 01/19/17)
Dr Glesby has received research support, paid to his institution, from Gilead Sciences, Inc (pending as of January 2017). (Updated 01/17/17)
Dr Gulick has no relevant financial affiliations to disclose. (Updated 01/22/17)
Dr Marrazzo has no relevant financial affiliations to disclose. (Updated 01/19/17)
Dr Hirsch has no relevant financial affiliations to disclose. (Updated 06/05/16)
Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 01/31/17)
Dr Richman has been a consultant to Antiva Biosciences, Chimerix, Gilead Sciences, Inc, and Monogram Biosciences, Inc. (Updated 01/20/17)
Dr Saag has received research grants and support awarded to his institution from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Inc, Merck & Co, Inc, and ViiV Healthcare. He has served as a consultant for Bristol-Myers Squibb, Gilead Sciences, Inc, Teva Pharmaceutical Industries, Ltd, and Merck & Co, Inc. (Updated 01/21/17)
Dr Schooley was awarded research grants, paid to his institution, from AbbVie, Bristol-Myers Squibb, and Merck & Co, Inc. His institution has received payment for his consultative advice or data monitoring committee service from Gilead Sciences, Inc, GlobeImmune, and Monogram Biosciences. He serves as a consultant to Antiva Biosciences, CytoDyn, and Farmak. He has stock options from Antiva Biosciences and CytoDyn. (Updated 01/19/17)
Dr Volberding has served on data and safety monitoring boards for Merck & Co, Inc. (Updated 01/17/17)
The nonstaff members of the Topics in Antiviral Medicine™ Editorial Board participate in a volunteer capacity. They are not compensated for their role in overseeing the program.
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors:
Independent educational grants for the 2016 Improving the Management of HIV Disease® CME program:
Gilead Sciences, Inc
Merck & Co, Inc
Drug and Product Disclaimer
This activity may contain information about the investigational uses of drugs or products that are not approved by the US Food and Drug Administration. Please consult full prescribing information before using any medication or product mentioned in this activity.
The views and opinions expressed herein are those of faculty and do not necessarily represent the opinions or recommendations of IAS–USA.
If you have any questions about this activity, please contact the IAS–USA:
Mail: 425 California Street, Suite 1450, San Francisco, CA 94104-2120
By clicking “Begin,” I acknowledge that I have read these instructions and understand them.
You must log in to take the activity.